Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Reexamination Certificate
2011-03-08
2011-03-08
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
C514S613000, C514S563000
Reexamination Certificate
active
07902260
ABSTRACT:
A medicament for preventive and/or therapeutic treatment of a lower urinary tract symptom caused by a lower urinary tract disorder, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2 -naphthalenyl)carbamoyl]benzoic acid.
REFERENCES:
patent: 4703110 (1987-10-01), Shudo
patent: 5733721 (1998-03-01), Hemstreet et al.
patent: 5929069 (1999-07-01), Shudo
patent: 6329428 (2001-12-01), Yamauchi et al.
patent: 2008/0021108 (2008-01-01), Shudo et al.
patent: 61-022047 (1986-01-01), None
patent: 61-076440 (1986-04-01), None
patent: 10-059951 (1998-03-01), None
patent: 01/17480 (2001-03-01), None
patent: 03/024394 (2003-03-01), None
Webster Ninth Dictionary, 2000. Defintion of the term “to prevent”., p. 1.
Oikawa et al. European Journal of Pharmacology, Nov. 1993, vol. 249, Issues 1-2, pp. 113-116.
H. Kagechika et al., J. Med. Chem., 1988, vol. 31, pp. 2182-2192.
R.M. Evans, Science, 1988, vol. 240, pp. 889-895.
M. Petkovich et al., Nature, 1987, vol. 330, pp. 444-450.
D.J. Mangelsdorf et al., Nature, 1990, vol. 345, pp. 224-229.
Y. Hashimoto, Cell Structure and Function, 1991, vol. 16, pp. 113-123.
Y. Hashimoto et al., Biochem. Biophys. Res. Commun., 1990, vol. 166, No. 3, pp. 1300-1307.
S. Rohrmann et al., Urology, 2004, vol. 64, No. 3, pp. 504-509.
H. de The at al., in: Retinoids: 10 Years on. Ed. J.H. Saurat, Basel Kager, 1991, pp. 2-9.
T. Yamakawa et al., J. Med. Chem., 1990, vol. 33, pp. 1430-1437.
U.S. Appl. No. 11/670,126 to Shudo et al., filed Feb. 1, 2007.
U.S. Appl. No. 11/854,697 to Shudo et al., filed Sep. 12, 2007.
English language Abstract of JP 61-022047, Jan. 30, 1986.
English language Abstract of JP 61-076440, Apr. 18, 1986.
English language Abstract of JP 10-059951, Mar. 3, 1998.
“Hinyokika Ryoki ni Okeru Soyaku: Ensan Tamsulosin Oyobi Ensan Solifenancin”, Nippon Yakuri Gakkaishi, vol. 126, pp. 341-345, 2005.
Kawabe Kazuki, “Latest Frontiers in Pharmacotherapy for Benign Prostatic Hyperplasia”, Yakugaku Zasshi, vol. 126, pp. 199-206, 2006.
International Search Report issued in connection with PCT/JP2008/000377, mailed May 27, 2008.
International Preliminary Report on Patentability issued in connection with PCT/JP2008/000377, mailed Sep. 11, 2009.
Zou et al., “Identification of Effective Retinoids for Inhibiting Growth and Inducing Apoptosis in Bladder Cancer Cells”, The Journal of Urology, vol. 165, No. 3, pp. 986-992, 2001.
Yilmaz et al., “Adjuvant Effect of Vitamin A on Recurrent Lower Urinary Tract Infections” Pediatrics International, vol. 49, No. 3, pp. 310-313, 2007.
Tamibarotene AM 80, Retinobenzoic Acid, Tamibaro Drugs in R & D, vol. 5, No. 6, pp. 359-362, 2004.
Harris et al., “Potential Therapeutic Effect of All-Trans-Retinoic Acid for Interstitial Cystitis” Journal of Urology, vol. 181, No. 4, pp. 21-22, 2009.
Extended European Search Report issued in connection with EP08720291.7, dated Feb. 4, 2010.
“Hinyokika Ryoki ni Okeru Soyaku: Ensan Tamsulosin Oyobi Ensan Solifenancin”, Nippon Yakuri Gakkaishi, vol. 126, pp. 341-345, 2005.
Asao Tetsuji
Ishido Miwako
Shudo Koichi
Greenblum & Bernstein P.L.C.
Jean-Louis Samira
Kemphys Ltd.
Padmanabhan Sreeni
LandOfFree
Medicament for preventive and/or therapeutic treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicament for preventive and/or therapeutic treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicament for preventive and/or therapeutic treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2631595